

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 69806

Title: Targeting metabolism: A potential strategy for hematological cancer therapy

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02522888

Position: Editorial Board

Academic degree: BSc, MSc, PhD

Professional title: Associate Professor, Director

Reviewer's Country/Territory: United States

Author's Country/Territory: China

Manuscript submission date: 2021-07-15

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-07-15 14:11

Reviewer performed review: 2021-07-26 18:04

Review time: 11 Days and 3 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	 [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This manuscripts brings forward latest knowledge on the factors underlying therapy resistance in hematological cancers. Overall the hypothesis is centered on the altered metabolism in tumor microenvironment and how it promotes the observed resistance. The authors introduce the concept of resistance followed by individually highlighting the different pathways regulating therapy resistance. Specific sub-sections are dedicated to hypoxia, PI3K/Akt/mtor, Ras, NfkB among others. Next the authors describe different hematological cancer resistance and ways to target resistance. Newer concepts and drugs are discussed including microenvironment targeted approaches, long non-coding RNAs etc. The topic is very attractive and timely. Text is supported by 94 references. There are some minor limitations: The text is excellent. However, it should be supported by at least one table and one figure summarizing various intertwining pathways that support therapy resistance. One table could be for markers and second table for targeted drugs Authors should carefully check the paper for typos and grammar.